Objective: To explore the expression of I-5α-reductase (SRD5A1)and its prognostic role in prostate cancer .
Methods: Data about SRD5A1 were retrieved from the ONCOMINE database and the role of SRD5A1 in prostate cancer was analyzed.
Results: Totally, 992 studies of different types relevant to the expression of SRD5A1 were identified in the ONCOMINE database. The SRD5A1 expression was statistically significant in 239 of the studies, overexpressed in 157 (11 in prostate cancer) and underexpressed in the other 82 (3 in prostate cancer). Eighteen of the studies, with 1 068 samples, addressed the expression of SRD5A1 in prostate cancer and normal tissues, which was significantly higher in the former than in the latter tissue (P<0.05). In 3 of the studies, the SRD5A1 expression was high in primary prostate cancer and increased with its metastasis (P<0.0 5). Two of the studies with prognostic data showed a higher rate of postoperative biochemical recurrence and a higher total mortality rate in the patients with a high than in those with a low expression of SRD5A1 (P<0.05).
Conclusions: SRD5A1 is highly expressed in prostate cancer, especially in metastatic and castration-resistant prostate cancer and its expression is associated with the prognosis of prostate cancer, which may be an important target of medication for prostate cancer.
目的： 阐述I型5α还原酶（SRD5A1）在前列腺癌中的表达及意义。 方法： 检索ONCOMINE数据库中关于SRD5A1的信息，并对目前数据库中资料进行2次分析，对其在前列腺癌中的作用进行meta分析。结果： ONCOMINE数据库中共收集了992项不同类型SRD5A1的研究结果，关于SRD5A1表达有统计学差异的结果有239项，其中SRD5A1表达增高的有157项，表达降低的有82项。前列腺癌中高表达的有11项、低表达的有3项。共有18项研究涉及SRD5A1在前列腺癌组织和正常组织中的表达，包括1068例样本。SRD5A1在前列腺癌中的表达量高于正常组织（P<0.05）。而在其中3项研究中，SRD5A1不仅在前列腺癌中高表达，并且随着前列腺癌的转移，SRD5A1的表达量逐渐增高（P<0.05）。不仅如此，在2项有预后数据的研究中，高表达SRD5A1的患者术后生化复发率和总体死亡率较高，低表达SRD5A1的患者术后预后较好（P<0.05）。 结论： SRD5A1在前列腺癌组织，尤其是在转移性前列腺癌和去势抵抗性前列腺癌高表达，且与前列腺癌预后有关，其有可能成为前列腺癌肿瘤药物的重要靶点。.
Keywords: ONCOMINE; SRD5A1; prostate cancer.